Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). (Q36611825)
Jump to navigation
Jump to search
scientific article published on 3 October 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). |
scientific article published on 3 October 2006 |
Statements
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) (English)
A Tosoni
G Cavallo
R Bertorelle
V Gioia
M Biscuola
V Blatt
L Crinò
M Ermani
3 October 2006
1 reference
1 reference